Xilio Therapeutics To Participate In Novel Immuno-Oncology Panel At TD Cowen 44Th Annual Health Care Conference
Date
2/28/2024 4:18:01 PM
(MENAFN- GlobeNewsWire - Nasdaq) WALTHAM, Mass., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced that René Russo, Pharm.D., president and chief executive officer, will participate in the“Novel Immuno-Oncology” panel discussion during the TD Cowen 44th Annual health Care conference on Monday, March 4, 2024 at 10:30 am EST.
A live webcast can be accessed under“Events & Presentations” in the Investors & Media section of the Xilio Therapeutics website at . A replay of the webcast will be archived on the website for 30 days following the presentation.
About Xilio Therapeutics
Xilio Therapeutics is a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology (I-O) therapies with the goal of significantly improving outcomes for people living with cancer without the systemic side effects of current I-O treatments. The company is using its proprietary geographically precise solutions (GPS) platform to build a pipeline of novel, tumor-activated molecules, including antibodies, cytokines and other biologics, which are designed to optimize their therapeutic index and localize anti-tumor activity within the tumor microenvironment. Xilio is currently advancing multiple programs for tumor-activated I-O treatments in clinical development, as well as programs in preclinical development. Learn more by visiting and follow us on LinkedIn (Xilio Therapeutics, Inc. ).
This press release contains hyperlinks to information that is not deemed to be incorporated by reference in this press release.
| Contacts: | | |
| | | |
Investors:
Melissa Forst
Argot Partners
... | | Media:
Dan Budwick
1AB
dan@1abmedia |
| | | |
MENAFN28022024004107003653ID1107913809
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.